The Lancet Respiratory Medicine in conversation with
A podcast by The Lancet Group
156 Episoade
-
Yves Lacasse on long-term oxygen therapy for COPD
Publicat: 31.07.2022 -
Rachael Evans on living with long COVID
Publicat: 26.07.2022 -
Daniel Munblit and Dale Needham on core outcomes post-COVID-19
Publicat: 15.06.2022 -
Daiana Stolz on antibiotic stewardship in pneumonia
Publicat: 24.05.2022 -
Ablo Wachinou on sleep disordered breathing in Benin
Publicat: 08.04.2022 -
Peter Openshaw and Felicity Liew on corticosteroids in the early in the treatment of COVID
Publicat: 07.04.2022 -
Dinh Bui on preterm birth and lung function deficits
Publicat: 18.02.2022 -
Ruvim Izĭckson on a joint flu and COVID-19 vaccine
Publicat: 31.01.2022 -
Wisia Wedzicha on a vaccine for COPD
Publicat: 11.01.2022 -
Eileen Rubin on patient-centered ARDS
Publicat: 30.12.2021 -
Daniel Altmann on COVID boosters
Publicat: 30.11.2021 -
Michael Kreuter on interstitial lung disease
Publicat: 06.09.2021 -
Bairbre McNicholas and Jie Li on awake prone positioning and COVID-19
Publicat: 20.08.2021 -
Charles Sprung and authors on end-of-life practices in ICUs globally
Publicat: 03.08.2021 -
Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma
Publicat: 10.07.2021 -
Paul Verweij on COVID-19 associated aspergillosis
Publicat: 26.05.2021 -
Ignacio Rubio on COVID-19 pathophysiology and phenotypes
Publicat: 17.05.2021 -
Kiran Shekar on cytokine adsorption and severe COVID-19 pneumonia
Publicat: 14.05.2021 -
Fan Chung on chronic cough and long COVID
Publicat: 11.05.2021 -
Mepolizumab and the treatment of chronic rhinosinusitis
Publicat: 16.04.2021
Editors at The Lancet Respiratory Medicine, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.A monthly audio companion to the journal, this podcast covers a broad range of topics, from long COIVD outcomes to tobacco control, the management of uncontrolled asthma to intensive care medicine, and more.
